Primary systemic amyloidosis, also called systemic AL amyloidosis or systemic immunoglobulin light chain amyloidosis, is described in the packet definition as a form of AL amyloidosis. The definition attributes it to aggregation and deposition of insoluble amyloid fibrils derived from misfolded monoclonal immunoglobulin light chains, usually produced by a plasma cell tumor, with multiple organ involvement. The packet carries Orphanet and GARD identifiers but no GeneReviews chapter and no onset category. Its prevalence field is not summarized here because the recorded category appears inconsistent with the condition's description.

The packet contains no structured phenotype records, characteristic findings, or onset information, so symptom frequencies are unknown in this packet. The only clinical description available is the definition's statement that the condition is characterized by multiple organ involvement.

The structured gene field and inheritance field are empty in this packet, so no genes or inheritance pattern are named; this reflects the packet and is not a statement that none exist. The definition describes the mechanism as deposition of amyloid fibrils derived from misfolded monoclonal immunoglobulin light chains, usually produced by a plasma cell tumor.

The packet contains no diagnostic methods field and no GeneReviews diagnosis content, so how the condition is identified is not described here.

The packet contains no certified approved-treatments or foundational-therapies fields, and no GeneReviews management content, so a treatment approach is not described here. The orphan-drug records include one entry with status APPROVED and an indication of light-chain (AL) amyloidosis, one DESIGNATED diagnostic agent for immunoglobulin light chain amyloidosis, and one WITHDRAWN designation; a designation is not marketing approval, and a withdrawn record is not a current option. Another designated record concerns an unrelated indication.

Prognosis is not certified in this packet, and no natural-history or survival information is provided.

The packet lists ten ClinicalTrials.gov records, with status and dates as recorded. Examples include NCT05898646, a Phase 2 daratumumab maintenance study in light chain amyloidosis (sponsor Mayo Clinic, RECRUITING, 2023-09-06 to 2031-11-30); NCT05451771, a Phase 1 venetoclax-dexamethasone study in relapsed or refractory t(11;14) amyloidosis (Columbia University, ACTIVE_NOT_RECRUITING); NCT06569147, a Phase 1 elranatamab study in relapsed or refractory AL amyloidosis (Dana-Farber Cancer Institute, RECRUITING); and NCT07172243, a biobank and data registry (Universitaire Ziekenhuizen KU Leuven, RECRUITING). The packet's literature digest classifies 175 publications, most commonly reviews or meta-analyses. No patient organizations are listed in the packet.